Gene Amplification of ErbB-2: From Gene to Therapy

Part of the Medical Radiology book series (MEDRAD)


Breast cancer remains the second leading cause of cancer-related deaths worldwide. One of the main obstacles for finding a cure for breast cancer is the inherent heterogeneity of the disease. There are three main subtypes which include estrogen and/or progesterone (ER/PR)-positive, epidermal growth factor receptor-2 (ErbB-2/HER2)-positive, and triple negative that lack expression of ER or PR and express wild type levels of ErbB-2. The etiology of breast cancer development termed the tumorigenic process has been closely linked to gene amplification. Several genes have been shown to be amplified in breast cancer including the ErbB-2 gene on chromosome 17q12-21. The amplification of the ErbB-2 gene is a clear and defined indicator of ErbB-2-positive breast cancer development. In this chapter, we will review the classes of genes that are amplified and linked to breast cancer, discuss the significance of the ErbB-2 signaling pathway to breast cancer progression, targeted therapy, and drug resistance.


Breast Cancer Gene Amplification MUC4 Expression ErbB Family Trastuzumab Resistance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Further Reading

  1. Gajria D, Chandarlapaty S (2011) HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther 2:263–275CrossRefGoogle Scholar
  2. Mehta K, Osipo C (2009) Trastuzumab resistance: role for notch signaling. Sci World J 9:1438–1448CrossRefGoogle Scholar
  3. Moelans CB, de Weger RA, Monsuur HN, Vijzelaar R, van Diest PJ (2010) Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes. Mod pathol 7:1029–1039CrossRefGoogle Scholar
  4. Mukohara T (2011) Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer. Cancer Sci 1:1–8CrossRefGoogle Scholar
  5. Osipo C, Patel P, Rizzo P, Clementz AG, Hao L, Golde TE, Miele L (2008) ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor. Oncogene 37:5019–5032CrossRefGoogle Scholar
  6. Pandya K, Meeke K, Clementz AG, Rogowski A, Roberts J, Miele L, Albain KS, Osipo C (2011) Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence. Br J Cancer 6:796–806CrossRefGoogle Scholar
  7. Slamon D, Pegram M (2001) Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 28:13–19CrossRefPubMedGoogle Scholar
  8. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–712CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Molecular Biology ProgramLoyola University ChicagoMaywoodUSA
  2. 2.Department of Pathology/Oncology InstituteLoyola University ChicagoMaywoodUSA
  3. 3.Department of Microbiology and ImmunologyLoyola University ChicagoMaywoodUSA

Personalised recommendations